Medpace Holdings, Inc. (NASDAQ:MEDP), a commercial physical and biological research services provider, announced the resignation of board member Ashley M. Keating and the appointment of Dr. Dani S. Zander as her replacement, effective July 1, 2024. Dr. Zander will also join the Nominating and Governance Committee.
The departure of Ms. Keating, effective June 30, 2024, was not due to any disagreements with company operations, policies, or practices. Dr. Zander, a distinguished academic in pathology, was elected unanimously by the Board following a recommendation from the independent directors. She will serve as a Class III director until the 2025 Annual Meeting of Stockholders.
Dr. Zander holds the MacKenzie Chair of the Department of Pathology and Laboratory Medicine at the University of Cincinnati and is the Chief of Pathology and Laboratory Medicine for UC Health. Her professional background includes leadership roles at Penn State and faculty positions at the University of Texas Health Science Center at Houston and the University of Florida College of Medicine.
With a focus on lung cancer and lung transplantation research, Dr. Zander has contributed extensively to the field of pathology through publications, editorial roles, and leadership in various pathology societies. She has also been actively involved in education and mentorship, earning recognition for her teaching efforts.
Dr. Zander received her Bachelor of Arts in chemistry from New York University and her Doctor of Medicine from the University of Florida. As part of her directorship, she was granted an option to purchase 824 shares of Medpace common stock at the closing price on July 1, 2024, with a seven-year term. Additionally, Dr. Zander has entered into the company's standard indemnification agreement for directors and officers.
The information in this article is based on a press release statement from Medpace Holdings, Inc.
In other recent news, Medpace Holdings Inc . has seen a flurry of positive analyst activity. Baird increased its target for Medpace shares to $456, citing valuation methodologies such as price-to-earnings, discounted cash flow, and enterprise value to earnings before interest, taxes, depreciation, and amortization.
TD Cowen initiated coverage on Medpace with a Buy rating and a $452 price target, highlighting the company's potential for growth and market share expansion within the clinical contract research industry. Mizuho also initiated coverage on Medpace, assigning a Buy rating with a $435 price target, applauding Medpace's strong organic growth profile and robust financial position.
Lastly, Baird raised Medpace's stock price target from $446 to $454 following strong financial results that surpassed expectations. These recent developments underscore the confidence financial firms have in Medpace's performance and potential for growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.